Method for treating detrusor overactivity of lower urinary tract in patients with multiple sclerosis

Vesusten's intramuscular administration addresses the ineffectiveness and cost of current NGB treatments by reducing urgency and increasing bladder capacity in MS patients, enhancing their quality of life.

RU2865253C2Active Publication Date: 2026-07-01БЕЛОУСОВ ИГОРЬ ИВАНОВИЧ
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
RU · RU
Patent Type
Patents
Current Assignee / Owner
БЕЛОУСОВ ИГОРЬ ИВАНОВИЧ
Filing Date
2024-10-15
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

Current treatments for neurogenic overactive bladder (NGB) in multiple sclerosis (MS) patients, such as anticholinergics and botulinum toxin injections, are ineffective and costly, necessitating a more efficient and safer therapeutic approach.

Method used

Administering Vesusten, a peptide regulator, via intramuscular injection every three days for 10 doses to treat neurogenic detrusor overactivity, targeting bladder tissue specifically.

Benefits of technology

Vesusten significantly reduces urgency, pollakiuria, nocturia, and increases bladder capacity, improving quality of life by addressing NGB symptoms effectively and safely without side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000001
    Figure 00000001
  • Figure 00000002
    Figure 00000002
  • Figure 00000003
    Figure 00000003
Patent Text Reader

Abstract

FIELD: urology; neurology.SUBSTANCE: used to correct neurogenic overactive bladder (NOB) in patients with multiple sclerosis (MS). A patient with multiple sclerosis with neurogenic detrusor overactivity is prescribed treatment with the drug Vesusten 5 mg. Dosage regimen: intramuscular injection once every three days, course - 10 injections.EFFECT: method ensures a reduction in the frequency of urgency, pollakiuria, nocturia, urinary incontinence and an increase in the effective volume of the bladder, improving the patient's quality of life due to treatment with the drug Vesusten with the specified dosage regimen.1 cl, 2 tbl, 1 ex
Need to check novelty before this filing date? Find Prior Art